Skip to main content
SpringerLink
Log in

Hypofractionated stereotactic reirradiation for recurrent glioblastoma

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Treatment choices for recurrent glioblastoma patients are sparse and the results are not satisfactory. In this retrospective analysis, we evaluated the results of re-irradiation of locally recurrent glioblastoma patients with an image-guided, fractionated, frameless stereotactic radiotherapy (SRT) technique. We treated 37 patients with the diagnosis of recurrent glioblastoma from September 2009 to December 2011. SRT was performed in a median five fractions (range, 1–5 fractions) with CyberKnife® (Accuray Incorporated, Sunnyvale, CA, USA). The dose given ranged from 14 to 32 Gy (median, 30 Gy). The median volume of the GTV was 24 cc (range, 2–81 cc). Median follow-up was 9.3 months. Five patients had regression in their lesions, 14 had stable disease, progression was observed in eight patients, and seven patients had pseudoprogression. The median survival following SRT was 10.6 months (range, 1.1–20 months) and overall survival following initial treatment was 35.5 months. The time to progression following SRT was 7.9 months in median. Patients with pseudoprogression had significantly longer survival after the first magnetic resonance imaging (MRI) compared to those with regression, stable or progressive disease (p = 0.012). The median survival after SRT for patients with pseudoprogression was 20 months. Patients who had GTV <24 cc had significantly longer survival following SRT compared to those with lesions ≥24 cc (p = 0.015). Patients who had chemotherapy after SRT had a median survival of 16.8 months. This was 9.7 months for patients who were not prescribed any chemotherapy (p = 0.062).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu JQ, Smigal C, Thun MJ (2006) Cancer statistics. CA Cancer J Clin 56(2):106–130

    Article  PubMed  Google Scholar 

  2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, Van Den Weyngaert D, Kaendler S, Krauseneck P, Vinolas N, Villa S, Wurm RE, Maillot MHB, Spagnolli F, Kantor G, Malhaire JP, Renard L, De Witte O, Scandolaro L, Vecht CJ, Maingon P, Lutterbach J, Kobierska A, Bolla M, Souchon R, Mitine C, Tzuk-Shina T, Kuten A, Haferkamp G, de Greve J, Priou F, Menten J, Rutten I, Clavere P, Malmstrom A, Jancar B, Newlands E, Pigott K, Twijnstra A, Chinot O, Reni M, Boiardi A, Fabbro M, Campone M, Bozzino J, Frenay M, Gijtenbeek J, Brandes AA, Delattre JY, Bogdahn U, De Paula U, van den Bent MJ, Hanzen C, Pavanato G, Schraub S, Pfeffer R, Soffietti R, Weller M, Kortmann RD, Taphoorn M, Torrecilla JL, Marosi C, Grisold W, Huget P, Forsyth P, Fulton D, Kirby S, Wong R, Fenton D, Fisher B, Cairncross G, Whitlock P, Belanger K, Burdette-Radoux S, Gertler S, Saunders S, Laing K, Siddiqui J, Martin LA, Gulavita S, Perry J, Mason W, Thiessen B, Pai H, Alam ZY, Eisenstat D, Mingrone W, Hofer S, Pesce G, Curschmann J, Dietrich PY, Stupp R, Mirimanoff RO, Thum P, Baumert B, Ryan G, Br EORTC (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996

    Article  PubMed  CAS  Google Scholar 

  3. Oppitz U, Maessen D, Zunterer H, Richter S, Flentje M (1999) 3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation. Radiother Oncol 53(1):53–57

    Article  PubMed  CAS  Google Scholar 

  4. Durmaz R, Erken S, Arslantas A, Atasoy MA, Bal C, Tel E (1997) Management of glioblastoma multiforme with special reference to recurrence. Clin Neurol Neurosurg 99(2):117–123

    Article  PubMed  CAS  Google Scholar 

  5. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–4729. doi:10.1200/Jco.2007.12.2440

    Article  PubMed  CAS  Google Scholar 

  6. Combs SE, Widmer V, Thilmann C, Hof H, Debus J, Schulz-Ertner D (2005) Stereotactic radiosurgery (SRS)—treatment option for recurrent glioblastoma multiforme (GBM). Cancer 104(10):2168–2173. doi:10.1002/Cncr.21429

    Article  PubMed  Google Scholar 

  7. Chan TA, Weingart JD, Parisi M, Hughes MA, Olivi A, Borzillary S, Alahakone D, Detorie NA, Wharam MD, Kleinberg L (2005) Treatment of recurrent glioblastoma multiforme with gliasite brachytherapy. Int J Radiat Oncol 62(4):1133–1139. doi:10.1016/j.ijrobp.2004.12.032

    Article  Google Scholar 

  8. Nieder C, Grosu AL, Molls M (2000) A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev 26(6):397–409

    Article  PubMed  CAS  Google Scholar 

  9. Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23(34):8863–8869. doi:10.1200/Jco.2005.03.4157

    Article  PubMed  Google Scholar 

  10. Minniti G, Armosini V, Salvati M, Lanzetta G, Caporello P, Mei M, Osti MF, Maurizi RE (2011) Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. J Neurooncol 103(3):683–691. doi:10.1007/s11060-010-0446-8

    Article  PubMed  CAS  Google Scholar 

  11. Hoffman WF, Levin VA, Wilson CB (1979) Evaluation of malignant glioma patients during the postirradiation period. J Neurosurg 50(5):624–628. doi:10.3171/jns.1979.50.5.0624

    Article  PubMed  CAS  Google Scholar 

  12. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE (2007) Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82(1):81–83. doi:10.1007/s11060-006-9241-y

    Article  PubMed  Google Scholar 

  13. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972. doi:10.1200/JCO.2009.26.3541

    Article  PubMed  Google Scholar 

  14. de Wit MCY, de Bruin HG, Eijkenboom W, Smitt PAES, van den Bent MJ (2004) Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63(3):535–537

    Article  PubMed  Google Scholar 

  15. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26(13):2192–2197. doi:10.1200/Jco.2007.14.8163

    Article  PubMed  Google Scholar 

  16. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PAES, van Es CA, van den Bent MJ (2008) Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113(2):405–410. doi:10.1002/Cncr.23562

    Article  PubMed  CAS  Google Scholar 

  17. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, Gilbertson RJ (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11(1):69–82. doi:10.1016/j.ccr.2006.11.020

    Article  PubMed  CAS  Google Scholar 

  18. Fuks Z, Kolesnick R (2005) Engaging the vascular component of the tumor response. Cancer Cell 8(2):89–91. doi:10.1016/j.ccr.2005.07.014

    Article  PubMed  CAS  Google Scholar 

  19. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300(5622):1155–1159

    Article  PubMed  CAS  Google Scholar 

  20. Lederman G, Wronski M, Arbit E, Odaimi M, Wertheim S, Lombardi E, Wrzolek M (2000) Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol 23(2):155–159

    Article  PubMed  CAS  Google Scholar 

  21. Hudes RS, Corn BW, Werner-Wasik M, Andrews D, Rosenstock J, Thoron L, Downes B, Curran WJ (1999) A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol 43(2):293–298

    Article  CAS  Google Scholar 

  22. Fokas E, Wacker U, Gross MW, Henzel M, Encheva E, Engenhart-Cabillic R (2009) Hypofractionated stereotactic re-irradiation of recurrent glioblastomas: the Marburg experience. Strahlenther Onkol 185:17

    Article  Google Scholar 

  23. Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol 75(1):156–163. doi:10.1016/j.ijrobp.2008.10.043

    Article  CAS  Google Scholar 

  24. Vordermark D, Kolbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M (2005) Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer 5:55. doi:10.1186/1471-2407-5-55

    Article  PubMed  PubMed Central  Google Scholar 

  25. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85(9):704–710

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by Hacettepe Resarch Grant 1 05 A 101 009.

Conflict of interest

No conflict of interest exists.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara, Turkey

    Gozde Yazici, Mustafa Cengiz, Gokhan Ozyigit, Gulnihan Eren, Ferah Yildiz, Fadil Akyol, Murat Gurkaynak & Faruk Zorlu

Authors
  1. Gozde Yazici
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mustafa Cengiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gokhan Ozyigit
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gulnihan Eren
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ferah Yildiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fadil Akyol
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Murat Gurkaynak
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Faruk Zorlu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mustafa Cengiz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yazici, G., Cengiz, M., Ozyigit, G. et al. Hypofractionated stereotactic reirradiation for recurrent glioblastoma. J Neurooncol 120, 117–123 (2014). https://doi.org/10.1007/s11060-014-1524-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-014-1524-0

Keywords

Search

Navigation